TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02363959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 2 hours of breathing \>99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Biopsy of Airway Epithelium
Description: During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endobronchial Biopsy of Airway Epithelium
Description: During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
Study: NCT03469791

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of Degenerative Spondylolisthesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of Degenerative Spondylolisthesis
Study: NCT03421106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Food Pantries
Description: Food pantries will receive consulting services to transform their food offerings and environment in order to influence client health behaviors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Food Pantries
Description: Normal food pantry use
Study: NCT04153682

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Testing
Description: Automated microbiological diagnostic device based on multiplex PCR analysis, allowing detection of multiple pathogens and resistance markers in one hour from invasive and non-invasive respiratory samples

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship
Description: After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial stewardship
Description: After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).
Study: NCT00289926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dehydroepiandrosterone
Description: dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
Study: NCT03801226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two-hour dwell with 10% dextrose in sterile water
Description: Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two-hour dwell with 10% dextrose in sterile water
Description: Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose
Description: Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose
Description: Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
Study: NCT04446065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Previfenon®
Description: Every capsule of Previfenon® (patent pending) provides 250 mg EGCG ≥ 98% purity with a carefully selected set of excipients to improve flowability, stabilize EGCG against early auto-oxidation, and increase its hepatoprotective activity with prolonged use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo starch capsules (250 mg plus excipients) identical in appearance and taste to Previfenon® capsules in a double-blind manner.
Study: NCT00112242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A ELA + Montanide
Description: A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide
Description: A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months.
Study: NCT04123405

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to acetylcysteine
Study: NCT03692715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Oral or intravenous ciprofloxacin prior to shockwave lithotripsy.
Study: NCT00112242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG
Description: A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG
Description: A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2
Description: A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months.
Study: NCT02284503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: The subjects will receive intensive Rosuvastatin before and after PCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: The subjects will receive intensive Rosuvastatin before and after PCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: The subjects will receive intensive Rosuvastatin before and after PCI
Study: NCT00323414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyunsaturated fatty acid (Opti-EPA)
Description: Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
Study: NCT03161483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo QD PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo QD PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo QD PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD PO
Study: NCT01503827

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Description: A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
Study: NCT00744029

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: educational material
Description: Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
Study: NCT03692715

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
Study: NCT00733005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo nasal spray
Description: Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
Study: NCT04038580

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laminated Socket
Description: This is the currently prescribed socket the participant normally wears.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quatro
Description: The Quatro (Quorum) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infinite Socket
Description: The Infinite Socket (LiM Innovations) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CJ Socket
Description: The CJ Socket (CJ Socket Technologies) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
Study: NCT01094704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride (7%)
Description: 4mL nebulized 7% sodium chloride
Study: NCT00003199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study: NCT01707667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prucalopride
Description: One 2 mg tablet orally administered on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG 3350
Description: 13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
Study: NCT04506658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.
Description: Patient in lithotomy position (supine) with return plate at lumbar level.~Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient's body.~Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.
Description: Doctor uses sham sensor to reduce efficiency to zero.
Study: NCT02868294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fassier-Duval Nail
Description: Implementation of a telescopic system intramedullary
Study: NCT00003199

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study: NCT01050998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 10 mg
Description: Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 30 mg
Description: Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 50 mg
Description: Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg
Description: Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
Study: NCT02287831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells
Study: NCT04176172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants will receive open-label varenicline for 12 weeks.
Study: NCT00003199

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous peripheral blood stem cell infusion
Study: NCT04176172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Participants will receive open-label varenicline for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment + Managed Problem Solving (MAPS) adherence intervention
Description: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.
Study: NCT01533974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance & Commitment Therapy (ACT)
Description: We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The control condition will be the current group-delivered CBT smoking cessation program at GH.
Study: NCT01939015

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D titanium miniplate
Description: for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
Study: NCT00003199

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: May undergo radiotherapy after completion of IL-2/GM-CSF
Study: NCT04627207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 1 Tab. and D085 1 Tab.
Description: Other names: Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 1 Tab. and D085 1 Tab.
Description: Other names: Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 1 Tab. and D085 1 Tab.
Description: Other names: Reference
Study: NCT01939015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D titanium miniplate
Description: for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard titanium miniplate- single non compression miniplate
Description: single non compression miniplate placed at superior border with monocortical screws via intraoral approach

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard titanium miniplate- single non compression miniplate
Description: single non compression miniplate placed at superior border with monocortical screws via intraoral approach
Study: NCT02788981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
Study: NCT04627207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 1 Tab
Description: Other names: Test
Study: NCT02389894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardioGard Cannula
Description: CardioGard Cannula, per the manufacturer's instructions for use (IFU).
Study: NCT02788981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Patients will either receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle) or patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle). Patients will receive mifepristone and nab-paclitaxel, or placebo and nab-paclitaxel. Not all three.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Patients will either receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle) or patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle). Patients will receive mifepristone and nab-paclitaxel, or placebo and nab-paclitaxel. Not all three.
Study: NCT04627207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 1 Tab
Description: Other names: Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 1 Tab
Description: Other names: Test
Study: NCT04221646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with study device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with study device.
Study: NCT04532814

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Cycling 60% VO2 max

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cycling 60% VO2 max
Study: NCT01996280

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motivational Interviewing
Description: The MI is a single brief motivational intervention lasting 1.5 hrs. The MI includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan; It is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored MI
Description: CTMI is a single brief motivational intervention lasting 1.5hrs. The CTMI follows the same sequence of structured strategies as the MI arm, and while the components in CTMI and MI are parallel, the focus within them is different. CTMI components culturally relevant material, such as acculturation stress. The CTMI components, which are MI structured strategies, are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback element, such as ethnic normative feedback related to drinking.
Study: NCT02424175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Study: NCT03628976

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tVNS
Description: Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tVNS
Description: Intervention

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Motor training
Description: Same finger training for both arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor training
Description: Same finger training for both arms
Study: NCT03722394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: 15 minute verbal one-on-one education session